Klebsi-mAb

Applicant: Prof. Dr. Tim Rollenske (Cluster: Immunity)

Recipient of MCID Career Development Grant

Now: Institute of Molecular Medicine and Experimental Immunology, University of Bonn; Previously: University of Bern Department of Biomedical Research (DBMR) and University Clinic of Visceral Surgery and Medicine

Status: Ongoing

The gram-negative bacterium Klebsiella pneumoniae (Kp) is a common member of our intestinal microbiota. But it is also an opportunistic pathogen and major cause of nosocomial infection with increasing antibiotic resistance mainly infecting newborns, the elderly or immunocompromised. As no vaccine for Kp exists, passive immunization with antigen-specific monoclonal antibodies (mAbs) is considered a potential pre-emptive therapy or treatment option to circumvent antibiotic resistance. Here, we study the intestinal antibody response to Kp in gnotobiotic animal models using single B cell receptor sequencing, Ig gene repertoire analysis and recombinant antibody expression with the aim to identify protective Kp-reactive mAbs.

Project-linked publication

  • Efficient Expression and Purification of Recombinant Mouse Dimeric IgA. 2025. Geisse, A., Zhang, T., Schreiber, J., Markova, K., Burkhalter, S., Wardemann, H., Macpherson, A. J., & Rollenske, T. H. European Journal of Immunology. Link: article

Project news

Article in The SPREAD, the MCID newsletter (February 2024)